Binge Eating Disorders Market - A Global and Regional Analysis

2.1 Antidepressant
2.2 Anticonvulsant
2.3 Anti-obesity
2.4 Others

3.1 North America
      3.1.1 Market Dynamics
      3.1.2 Market Sizing and Forecast
      3.1.3 North America Binge Eating Disorders Market, by Country ($Million), 2023-2035
               3.1.3.1 U.S.
               3.1.3.2 Canada
3.2 Europe
      3.2.1 Market Dynamics
      3.2.2 Market Sizing and Forecast
      3.2.3 Europe Binge Eating Disorders Market, by Country ($Million), 2023-2035
               3.2.3.1 U.K.
               3.2.3.2 France
               3.2.3.3 Germany
               3.2.3.4 Italy
3.2.3.5 Spain
3.2.3.6 Rest-of-Europe
3.3 Asia-Pacific
      3.3.1 Market Dynamics
      3.3.2 Market Sizing and Forecast
      3.3.3 Asia-Pacific Binge Eating Disorders Market, by Country ($Million), 2023-2035
               3.3.3.1 Japan
               3.3.3.2 China
               3.3.3.3 India
               3.3.3.4 Australia
               3.3.3.5 South Korea
               3.3.3.6 Rest-of-Asia-Pacific
3.4 Rest-of-the-World
      3.4.1 Market Dynamics
      3.4.2 Market Sizing and Forecast Rest-of-the-World Binge Eating Disorders Market, by Type ($Million), 2023-2035
      3.4.3 Rest-of-the-World Binge Eating Disorders Market, by Country ($Million), 2023-2035
               3.4.3.1 Latin America
               3.4.3.2 Middle East and Africa

4.1 Competitive Landscape
      4.1.1 Mergers and Acquisitions
      4.1.2 Partnership, Alliances and Business Expansion
      4.1.3 New Offerings
      4.1.4 Regulatory Activities
      4.1.5 Funding Activities
4.2 Company Profiles
      4.2.1 Eli Lilly and Company
               4.2.1.1 Overview
               4.2.1.2 Top Products / Product Portfolio
               4.2.1.3 Top Competitors
               4.2.1.4 Target Customers/End-Users
               4.2.1.5 Key Personnel
               4.2.1.6 Analyst View
      4.2.2 Amneal Pharmaceuticals, Inc.
               4.2.2.1 Overview
               4.2.2.2 Top Products / Product Portfolio
               4.2.2.3 Top Competitors
               4.2.2.4 Target Customers/End-Users
               4.2.2.5 Key Personnel
               4.2.2.6 Analyst View
      4.2.3 Takeda Pharmaceutical, Ltd.
               4.2.3.1 Overview
               4.2.3.2 Top Products / Product Portfolio
               4.2.3.3 Top Competitors
               4.2.3.4 Target Customers/End-Users
               4.2.3.5 Key Personnel
               4.2.3.6 Analyst View
      4.2.4 Tryp Therapeutics Inc
               4.2.4.1 Overview
               4.2.4.2 Top Products / Product Portfolio
               4.2.4.3 Top Competitors
               4.2.4.4 Target Customers/End-Users
               4.2.4.5 Key Personnel
               4.2.4.6 Analyst View
      4.2.5 Tonix Pharmaceuticals Corp.
               4.2.5.1 Overview
               4.2.5.2 Top Products / Product Portfolio
               4.2.5.3 Top Competitors
               4.2.5.4 Target Customers/End-Users
               4.2.5.5 Key Personnel
               4.2.5.6 Analyst View
      4.2.6 Sumitomo Pharma Ltd.
               4.2.6.1 Overview
               4.2.6.2 Top Products / Product Portfolio
               4.2.6.3 Top Competitors
               4.2.6.4 Target Customers/End-Users
               4.2.6.5 Key Personnel
               4.2.6.6 Analyst View
      4.2.7 VIVUS Inc
               4.2.7.1 Overview
               4.2.7.2 Top Products / Product Portfolio
               4.2.7.3 Top Competitors
               4.2.7.4 Target Customers/End-Users
               4.2.7.5 Key Personnel
               4.2.7.6 Analyst View
      4.2.8 Novartis AG
               4.2.8.1 Overview
               4.2.8.2 Top Products / Product Portfolio
               4.2.8.3 Top Competitors
               4.2.8.4 Target Customers/End-Users
               4.2.8.5 Key Personnel
               4.2.8.6 Analyst View
      4.2.9 Pfizer Inc.
               4.2.9.1 Overview
               4.2.9.2 Top Products / Product Portfolio
               4.2.9.3 Top Competitors
               4.2.9.4 Target Customers/End-Users
               4.2.9.5 Key Personnel
               4.2.9.6 Analyst View
      4.2.10 Others

Table: Global Binge Eating Disorders Market (by Drug Class), $Million, 2023-2035
Table: Global Binge Eating Disorders Market (by Region), $Million, 2023-2035"
 

Figure: Global Binge Eating Disorders Market Coverage
Figure: Global Binge Eating Disorders Market Key Trends, Impact Analysis, 2023-2035
Figure: Global Binge Eating Disorders Market, Patent Analysis, January 2022-May 2025